• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Home > Stories

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
16 Mar 2023
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

When Davide Paparo and Ian Häusler, two engineering students from the Zurich University of Applied Sciences, chose their graduation project two years ago, they had no idea they would embark on an extraordinary journey to potentially bring a new medical machine to the thousands of people affected by cutaneous leishmaniasis – a neglected parasitic disease that causes disfiguring skin lesions. 

And they never knew that ‘simple’ heat could provide a cure for a disease which is currently mainly treated by toxic and often ineffective drugs.

‘I had never heard of this disease before we started our research,’ recalls Davide Paparo. ‘But once we began talking with doctors and experts in Peru and Guatemala, where the disease is endemic, we realized how big the problem is – and that we had the potential to help.’ 

Cutaneous leishmaniasis is a parasitic disease transmitted by the bite of a sandfly. Up to one million people are infected every year. This ‘flesh eating parasite’ causes skin lesions, which look like open wounds, on the face or other exposed areas, and leaves permanent, disfiguring scars. Affected people, especially women and children, are often ostracized and stigmatized within their community. The disease is endemic in 89 countries, including in Latin American countries such as Brazil, Colombia, and Peru.

Man standing in front of his home in Colombia
Man showing a skin lesion on his arm

Fruit farmer Jorge Hernandez from Colombia has skin lesions on his arm due to cutaneous leishmaniasis. Watch his story

‘Cutaneous leishmaniasis is neglected by traditional pharmaceutical research. Existing drug treatments are outdated, toxic medicines that were developed more than 60 years ago,’ explains Dr Byron Arana, Head of Cutaneous Leishmaniasis at DNDi.

‘Antimonial treatments, for example, involve painful injections given in hospital for 21 days. These forms of treatment are long and toxic, and their effectiveness can be low. Fortunately, for uncomplicated cases of cutaneous leishmaniasis, thermotherapy is a good option. This is how we brought the idea of building a new thermotherapy machine to the Zurich University of Applied sciences.’ 

In theory, thermotherapy for cutaneous leishmaniasis is simple: you apply the right level of heat to the lesion to kill the parasite and cure the patient.

In practice, it is much more complex – and this is where Paparo and Häusler put their skills to good use. 

‘You need to apply heat at a very precise depth, 2 to 5 mm under the skin, for 30 seconds. If you exceed that temperature, it may cause second degree burns,’ explains Paparo.

‘You also need to make the device portable and robust enough to be used in all types of environments, not only at the hospital. And of course, the most important is to make the machine affordable, so it can reach as many patients as possible.’

Davide Paparo

After speaking with doctors in endemic countries and DNDi researchers to learn as much as possible about the disease and the type of device practitioners need, the two students set to work. They found an innovative way to measure skin temperature using an infrared sensor. They wanted to make thermotherapy a whole lot safer and were also able to reduce the manufacturing costs significantly. 

To reach the deeper layers of the skin, the machine uses radio frequency: two electrodes applied to the lesion generate an electromagnetic field that results in heat. ‘It is actually very hot, that is why it is critical not to exceed the target temperature,’ says Paparo. In the initial development phase, the two students tried the electrodes… on themselves. David Paparo still has a small burn mark on his forearm from this trial-and-error process. ‘Our machine is now very safe,’ he smiles.  

Many people with cutaneous leishmaniasis live in rural areas and must travel long distances to go to hospital and get treatment, so Paparo and Häusler wanted their device to be portable and suited to use in rough conditions, and to have a long battery life. ‘We designed the housing to withstand humidity, light rain, and also shocks.’ 

‘At the end of our bachelor studies, we had this great product in our hands, and it showed a lot of potential in terms of treatments. It became pretty clear to us that we should pursue this. Our goal is now to bring as many devices as possible to patients and make thermotherapy accessible to everyone who needs it.’

Davide Paparo

Setting their sights on achieving this, Davide Paparo and Ian Häusler decided to create their own startup, DermatoTherma, to bring their device to market. 

They know they still have a long way ahead of them. Clinical studies need to be conducted to demonstrate the safety and efficacy of the device in comparison to the existing device, which has been designed in the 80s, and to register it with the relevant regulatory authorities. But they have good reasons for optimism: their startup already received two grants from foundations in Switzerland to support its development. 

‘Now we need to find investors who are not only interested in revenue but also in social impact,’ says Paparo.

‘We need people who see the need for this machine and believe in the startup to build a sustainable revenue stream, not people who want to make as much money as possible in the shortest possible time.’

Davide Paparo

Now with their bachelor’s degree in hand, the two engineers are brimming with new ideas to continue improving their machine. ‘We are developing a smart system that will allow the device to automatically detect the part of the body the electrodes are applied to. If you treat the arm, or the face, you will have different skin characteristics – and different electrical properties. Being able to detect those would help control the output more precisely and improve the device’s safety,’ says Paparo. 

During development, they faced a gap in data that is all too familiar to researchers of neglected diseases: ‘We realized that most of the existing human skin data we needed is from white males, but there is little data on women, Latinxs, etc. We want to contribute to building a more diverse database that can be used by medical scientists to support further research in this field,’ says Davide Paparo. ‘A more representative database could really boost future discoveries.’

More information

  • Visit the DermatoTherma website

Photo credit: ©BOOSTR; Sydelle Willow Smith-DNDi

Cutaneous leishmaniasis Latin America Europe

Read, watch, share

Loading...
Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

Woman in rural setting
Viewpoints
18 Feb 2023

Africa is winning the war against Neglected Tropical Diseases

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo